ES-SCLC Patients with PD-L1⁺ CTCs and High Percentages of CD8⁺PD-1⁺T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment.

ABSTRACT: SCLC is an aggressive cancer type with high metastatic potential and bad prognosis. CTCs are a valuable source of tumor cells in blood circulation and are among the major contributors to metastasis. In this study we evaluated the number of CTCs that express PD-L1 in treatment-naïve ES-SCLC patients receiving ICI in a front-line setting. Moreover, we explored the percentages of different immune T-cell subsets in circulation to assess their potential role in predicting responses. A total of 43 patients were enrolled-6 of them with LS-SCLC, and 37 with ES-SCLC disease. In addition, PBMCs from 10 healthy donors were used as a control group. Different T-cell subtypes were examined through multicolor FACS analysis and patients' CTCs were detected using immunofluorescence staining. SCLC patients

SUBMITTER: Xagara A 

PROVIDER: S-EPMC10813758 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature